Jeffrey I Traylor1, Hadley E Sheppard2, Visweswaran Ravikumar3, Jonathan Breshears1, Shaan M Raza1, Charles Y Lin2,4, Shreyaskumar R Patel5, Franco DeMonte1. 1. Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas. 3. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Kronos Bio, Cambridge, Massachusetts. 5. Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Chordomas are aggressive bone tumors that often recur despite maximal resection and adjuvant radiation. To date there are no Food and Drug Administration (FDA)-approved chemotherapies. Computational drug repositioning is an expanding approach to identify pharmacotherapies for clinical trials. OBJECTIVE: To identify FDA-approved compounds for repurposing in chordoma. METHODS: Previously identified highly differentially expressed genes from chordoma tissue samples at our institution were compared with pharmacogenomic interactions in the Comparative Toxicogenomics Database (CTD) using ksRepo, a drug-repositioning platform. Compounds selected by ksRepo were then validated in CH22 and UM-Chor1 human chordoma cells in Vitro. RESULTS: A total of 13 chemical compounds were identified in silico from the CTD, and 6 were selected for preclinical validation in human chordoma cell lines based on their clinical relevance. Of these, 3 identified drugs are FDA-approved chemotherapies for other malignancies (cisplatin, cytarabine, and lucanthone). Cytarabine, a deoxyribonucleic acid polymerase inhibitor approved for the treatment of various leukemias, exhibited a significant concentration-dependent effect against CH22 and UM-Chor1 cells when compared to positive (THZ1) and negative (venetoclax) controls. Tretinoin exhibited a significant concentration-dependent cytotoxic effect in CH22, sacral chordoma-derived cell lines but to a much lesser extent in UM-Chor1, a cell line derived from skull base chordoma. CONCLUSION: Cytarabine administration reduces the viability of human chordoma cells. The equally effective reduction in viability seen with tretinoin seems to be cell line dependent. Based on our findings, we recommend the evaluation of cytarabine and tretinoin in an expanded set of human chordoma cell lines and animal models.
BACKGROUND: Chordomas are aggressive bone tumors that often recur despite maximal resection and adjuvant radiation. To date there are no Food and Drug Administration (FDA)-approved chemotherapies. Computational drug repositioning is an expanding approach to identify pharmacotherapies for clinical trials. OBJECTIVE: To identify FDA-approved compounds for repurposing in chordoma. METHODS: Previously identified highly differentially expressed genes from chordoma tissue samples at our institution were compared with pharmacogenomic interactions in the Comparative Toxicogenomics Database (CTD) using ksRepo, a drug-repositioning platform. Compounds selected by ksRepo were then validated in CH22 and UM-Chor1 human chordoma cells in Vitro. RESULTS: A total of 13 chemical compounds were identified in silico from the CTD, and 6 were selected for preclinical validation in human chordoma cell lines based on their clinical relevance. Of these, 3 identified drugs are FDA-approved chemotherapies for other malignancies (cisplatin, cytarabine, and lucanthone). Cytarabine, a deoxyribonucleic acid polymerase inhibitor approved for the treatment of various leukemias, exhibited a significant concentration-dependent effect against CH22 and UM-Chor1 cells when compared to positive (THZ1) and negative (venetoclax) controls. Tretinoin exhibited a significant concentration-dependent cytotoxic effect in CH22, sacral chordoma-derived cell lines but to a much lesser extent in UM-Chor1, a cell line derived from skull base chordoma. CONCLUSION: Cytarabine administration reduces the viability of human chordoma cells. The equally effective reduction in viability seen with tretinoin seems to be cell line dependent. Based on our findings, we recommend the evaluation of cytarabine and tretinoin in an expanded set of human chordoma cell lines and animal models.
Authors: Pierig Lepont; John T Stickney; Lauren A Foster; Jin-Jun Meng; Robert F Hennigan; Wallace Ip Journal: Mutat Res Date: 2007-08-06 Impact factor: 2.433
Authors: S Stacchiotti; A Gronchi; P Fossati; T Akiyama; C Alapetite; M Baumann; J Y Blay; S Bolle; S Boriani; P Bruzzi; R Capanna; A Caraceni; R Casadei; V Colia; J Debus; T Delaney; A Desai; P Dileo; S Dijkstra; F Doglietto; A Flanagan; S Froelich; P A Gardner; H Gelderblom; Z L Gokaslan; R Haas; C Heery; N Hindi; P Hohenberger; F Hornicek; R Imai; L Jeys; R L Jones; B Kasper; A Kawai; M Krengli; A Leithner; I Logowska; J Martin Broto; D Mazzatenta; C Morosi; P Nicolai; O J Norum; S Patel; N Penel; P Picci; S Pilotti; S Radaelli; F Ricchini; P Rutkowski; S Scheipl; C Sen; E Tamborini; K A Thornton; B Timmermann; V Torri; P U Tunn; M Uhl; Y Yamada; D C Weber; D Vanel; P P Varga; C L A Vleggeert-Lankamp; P G Casali; J Sommer Journal: Ann Oncol Date: 2017-06-01 Impact factor: 32.976
Authors: Stefan Gröschel; Daniel Hübschmann; Francesco Raimondi; Peter Horak; Gregor Warsow; Martina Fröhlich; Barbara Klink; Laura Gieldon; Barbara Hutter; Kortine Kleinheinz; David Bonekamp; Oliver Marschal; Priya Chudasama; Jagoda Mika; Marie Groth; Sebastian Uhrig; Stephen Krämer; Christoph Heining; Christoph E Heilig; Daniela Richter; Eva Reisinger; Katrin Pfütze; Roland Eils; Stephan Wolf; Christof von Kalle; Christian Brandts; Claudia Scholl; Wilko Weichert; Stephan Richter; Sebastian Bauer; Roland Penzel; Evelin Schröck; Albrecht Stenzinger; Richard F Schlenk; Benedikt Brors; Robert B Russell; Hanno Glimm; Matthias Schlesner; Stefan Fröhling Journal: Nat Commun Date: 2019-04-09 Impact factor: 14.919
Authors: Tanaz Sharifnia; Mathias J Wawer; Ting Chen; Qing-Yuan Huang; Barbara A Weir; Ann Sizemore; Matthew A Lawlor; Amy Goodale; Glenn S Cowley; Francisca Vazquez; Christopher J Ott; Joshua M Francis; Slim Sassi; Patricia Cogswell; Hadley E Sheppard; Tinghu Zhang; Nathanael S Gray; Paul A Clarke; Julian Blagg; Paul Workman; Josh Sommer; Francis Hornicek; David E Root; William C Hahn; James E Bradner; Kwok K Wong; Paul A Clemons; Charles Y Lin; Joanne D Kotz; Stuart L Schreiber Journal: Nat Med Date: 2019-01-21 Impact factor: 53.440